Results 81 to 90 of about 24,341 (292)

CD59, Disulphide‐Locked Human C9 and Horse C9 Inhibit Human Membrane Attack Complex Assembly by Similar Mechanisms

Immunology, EarlyView.
The membrane attack complex (MAC) is formed by the stepwise assembly of five proteins: C5b, C6, C7, C8 and C9. MAC plays a key role in driving inflammation in numerous diseases. This study compares the inhibitory mechanisms of MAC assembly by soluble CD59 (sCD59), a disulphide‐locked C9 mutant (C9lock) and horse C9 (HoC9).
Rebekah S. Cooke, Bradley A. Spicer, Richard A. Harrison, Michelle A. Dunstone, B. Paul Morgan, Wioleta M. Zelek   +5 more
wiley   +1 more source

Eculizumab experience in an adult patient with atypical hemolytic uremic syndrome

Saudi Journal of Kidney Diseases and Transplantation, 2017
Atypical hemolytic-uremic syndrome is a disease characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal failure. In this study, we present a case of a patient with atypical hemolytic-uremic syndrome treated successfully with eculizumab ...
Funda Sari, Ayça Inci, Volkan Karakus, Banu Yilmaz, Metin Sarikaya, Refik Olmaz, Erdal Kurtoglu   +6 more
doaj   +1 more source

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations [PDF]

, 2013
Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are ...
Alberti, M., Bresin, E., Galbusera, M., Noris, M., Piras, R., Remuzzi, G., Thaiss, F., TRIPODO, Claudio, Valoti, E.   +8 more
core   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

HUS and atypical HUS [PDF]

, 2017
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually categorized as typical, caused by Shiga toxin-producing Escherichia coli (STEC) infection,
Al-Nouri, Allen, Amaral, Ardissino, Arvidsson, Atefi, Atkinson, Berry, Bhakdi, Bhattacharjee, Boltax, Brady, Bresin, Bruneau, Bu, Caires, Campistol, Canalejo, Carson, Chapin, Chien, Cofiell, Cole, Conway, Conway, Coppo, Cornec-Le Gall, de Córdoba, Del Conde, Delvaeye, Dempsey, Devine, Dhakal, Dragon-Durey, Egbor, El-Husseini, Faguer, Fakhouri, Ferreira, Ferreira, Fremeaux-Bacchi, Frimat, George, Gilbert, Gorsuch, Gottschalk, Grabowski, Greenbaum, Hill, Hornung, Hosler, Huber-Lang, Hughson, Hyvärinen, Iida, Ikeda, Jin, Jokiranta, Kang, Karnchanaphanurach, Karpman, Karpman, Karpman, Kavanagh, Keir, Kielstein, Kim, Kourouklaris, Krisinger, Kronbichler, Laurence, Law, Lechner, Lehtinen, Lemaire, Licht, Liszewski, Loirat, Lupu, Manuelian, Martel, Mathew, Matsukuma, Mele, Meri, Morton, Moskovich, Mukhopadhyay, Nakakuma, Nester, Noris, Noris, Noris, Oikonomopoulou, Orth-Höller, Ozaki, Pangburn, Pangburn, Pape, Pecoraro, Pilzer, Podack, Ricklin, Rinder, Rodríguez-Pintó, Roumenina, Ruggenenti, Schutte, Scully, Sethi, Sims, Sinha, Song, Ståhl, Ståhl, Sung, Szilágyi, T. Sakari Jokiranta, Tawadrous, Tedesco, Thomas, Thurman, Toh, Tsai, Tufano, Vasu, Ward, Warwicker, Wehling, Wetsel, Whaley, Wiedmer, Wig, Woodworth, Zipfel, Zipfel   +135 more
core   +1 more source

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Pediatric nephrology (Berlin, West), 2020
Atypical hemolytic uremic syndrome (aHUS) is a rare, complement-mediated disease associated with poor outcomes if untreated. Ravulizumab, a long-acting C5 inhibitor developed through minimal, targeted modifications to eculizumab was recently approved for
Kazuki Tanaka, B. Adams, Á. M. Aris, N. Fujita, M. Ogawa, S. Ortiz, M. Vallée, L. Greenbaum   +7 more
semanticscholar   +1 more source

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial

Clinical and Translational Science, Volume 18, Issue 7, July 2025.
ABSTRACT HSK39297 is a novel complement factor B inhibitor, and this phase 1 trial was designed to assess its pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability in healthy Chinese subjects. This study included 46 subjects in the single ascending dose (SAD) part (50–600 mg) and 50 subjects in the multiple ascending dose (MAD) part ...
Yuyang Dai, Feng Wu, Siyang Ni, Xiaojun Hu, Ying Han, Ying Jiao, Huan Lu, Yilin Liu, Lingling Wang, Yunfei Lin, Meixia Chen, Chao Wang, Qinghe Wu, Fangqiong Li, Laichun Lu   +14 more
wiley   +1 more source

Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis

Frontiers in Immunology, 2021
Complement factor B (FB) mutant variants are associated with excessive complement activation in kidney diseases such as atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy and membranoproliferative glomerulonephritis (MPGN).
Sigridur Sunna Aradottir, A. Kristoffersson, L. Roumenina, A. Bjerre, Pavlos Kashioulis, R. Palsson, D. Karpman   +6 more
semanticscholar   +1 more source

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Romanian Journal of Internal Medicine, 2022
Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of ...
Yeter Hasan H., Derici Ulver, Arinsoy Turgay, Altok Kadriye, Erten Yasemin, Guz Galip   +5 more
doaj   +1 more source

Atypical hemolytic uremic syndrome : update on the complement system and what is new [PDF]

, 2010
Atypical hemolytic uremic syndrome (aHUS) is a rare disease of microangiopathic hemolytic anemia, thrombocytopenia, and predominant renal impairment. It is characterized by the absence of Shiga toxin-producing bacteria as a triggering factor.
Dickenmann, Michael, Hirt-Minkowski, Patricia, Schifferli, Jürg A.   +2 more
core   +1 more source